• Type:
  • Category:

Carl Zeiss Meditec AG Financial Results 9M 2022 /23 | Robust Growth and Strategic Plans with CEO

Share

Carl Zeiss Meditec AG 9M 2022/23: Key Takeaways

Presentation Overview

In a detailed summary presented by Carl Zeiss Meditec AG, the CEO and CFO provided a meticulous overview of the financial performance spanning the first three quarters of the fiscal year 2022/23. Celebrating another quarter of double-digit top-line growth, they acknowledged the robust and persistent efforts of the operations team, navigating through intricate supply chain conditions. Notwithstanding the progress on delivery timeframes, they highlighted the journey ahead for further advancements.

 

Investment and EBIT Dynamics

Investments have been strategically channelled into pivotal areas like research and development as well as sales and marketing, echoing the company’s allegiance to innovation and sustaining a formidable market presence. A modest growth was observed in the EBIT for Q3, year-on-year. Nonetheless, the company wrestles with margin pressures, attributed to a confluence of strategic investments and product mix dynamics.

 

Upcoming Strategic Focus

Carl Zeiss Meditec AG sets a bifocal future strategy: minimising the order backlog to normalise delivery timelines and navigating through uncertainties, including substantial consumable stocks and impending price regulation for intraocular lenses in China. Even amid these hurdles, management articulates confidence in attaining the anticipated full-year revenue markers of 2.1 billion Euros, with an EBIT margin between 17 to 20%, albeit potentially skirting the lower boundary of this spectrum.

 

Strategic Investment Insights

Strategic Avenues and Ongoing Acquisitions

The leadership team, comprised of the CEO and CFO, underscored their strategic investments and ongoing acquisitions as a precursor for imminent growth and scalability. Acknowledging the hurdles encountered throughout the year, including geopolitical tensions and escalating inflation, they voiced confidence in the ensuing visibility of the strategy’s dividends in the forthcoming years.

Chapters
  • About the 9M – 2022/23
  • Earnings Development
  • Expectations for Q4 2022/23 and 2023/24
  • CEO Remarks
Resources
Presentation
Carl Zeiss Meditec Video Hub
Podcast
Host
weber - Carl Zeiss Meditec AG Financial Results 9M 2022 /23 | Robust Growth and Strategic Plans with CEO -%sitename%

Dr. Markus Weber
CEO | Carl Zeiss Meditec AG

cfo - Carl Zeiss Meditec AG Financial Results 9M 2022 /23 | Robust Growth and Strategic Plans with CEO -%sitename%

Justus Felix Wehmer
CFO | Carl Zeiss Meditec AG

Linkedin
sebastian 1 - Carl Zeiss Meditec AG Financial Results 9M 2022 /23 | Robust Growth and Strategic Plans with CEO -%sitename%

Sebastian Frericks
Head IR | Carl Zeiss Meditec AG

Linkedin Envelope
Share
T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Continuing the Journey: More Presentations

Discover Additional Elevator Pitches

Release Date

August 4, 2023

Duration

03:13

Director

Reviews for Carl Zeiss Meditec AG Financial Results 9M 2022 /23 | Robust Growth and Strategic Plans with CEO
There are currently no reviews for Carl Zeiss Meditec AG Financial Results 9M 2022 /23 | Robust Growth and Strategic Plans with CEO
COMPANIES:

Germany:

Austria:

Estonia:

Finland:

France:

Italy:

Poland:

Spain:

PRESENTATIONS:
INDUSTRIES:
Linkedin Twitter Instagram Podcast Envelope Whatsapp

(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG 

Unlock the insights of top publicly listed companies with seat11a.com

Elevate your understanding with powerful Elevator Pitches, Deep-Dive Presentations, and in-depth Financial Analysis

Scroll to top